跳至主要内容
临床试验/NCT02238223
NCT02238223已完成不适用

Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Tablet

Boehringer Ingelheim0 个研究点目标入组 2,001 人开始时间: 2004年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
2,001
主要终点
Incidence of adverse drug reactions

研究概览

简要总结

Study to investigate the safety and efficacy information of Alesion® Tablet under the proper use in daily clinical practice after new treatment guideline for allergic rhinitis, bronchial asthma, eczema, dermatitis, urticaria, pruritus, prurigo and psoriasis vulgaris with itching

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • All the patients who:
  • haven't treatment experience of epinastine product;
  • have at least one out of following diseases. allergic rhinitis, eczema, dermatitis, pruritus, prurigo, urticaria, psoriasis with itching, bronchial asthma

排除标准

  • Alesion® Tablet is contraindicated for the patients with history of hypersensitivity to any ingredients of Alesion® Tablet in package insert. However, it is unknown whether a patient is hypersensitive to the ingredients of the product in almost cases. And this survey is drug utilization study to observe actual use in any patients. Therefore exclusion criteria is not set in the protocol

研究组 & 干预措施

Patients without experience in treatment with epinastine

干预措施: Alesion® (Drug)

结局指标

主要结局

Incidence of adverse drug reactions

时间窗: up to 24 months

classified by Medical Dictionary for Regulatory Activities (MedDRA)

Incidence of adverse drug reactions classified by patient's background/treatment factors

时间窗: up to 24 months

次要结局

  • Overall assessment of efficacy by investigator on a 3-point scale(after 24 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验